Eisai sales and marketing update

Eisai launched 5 and 10 mg Aciphex Sprinkle delayed-release rabeprazole capsules in the U.S. to treat gastroesophageal reflux disease (GERD) for up to 12 weeks in children ages one to 11 years. FDA approved the doses in April. A 20 mg tablet formulation of Aciphex is approved to treat daytime and nighttime heartburn in adults and adolescents. The wholesale acquisition cost of a 30-day supply of each of the three dose strengths is $349.90. ...